Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
about
Use of licensed vaccines for active immunization of the immunocompromised hostVirulence factors of medically important fungiNew insights on the development of fungal vaccines: from immunity to recent challengesHost immunity to Cryptococcus neoformansAntifungal Therapy: New Advances in the Understanding and Treatment of MycosisCryptococcal interactions with the host immune system.Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in miceCharacterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsuleBivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune miceThe capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyPersistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodiesThe common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies.Antifungal agents: chemotherapeutic targets and immunologic strategies.Fungal infections: a growing threatEvaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.Exploiting fungal cell wall components in vaccinesMonoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.Antifungal prophylaxis during neutropenia and immunodeficiencyAntibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophagesVariation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis.Capsular polysaccharide-protein conjugate vaccines of carbotype 1 Vibrio vulnificus: construction, immunogenicity, and protective efficacy in a murine modelAnalysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.Antibody immunity and invasive fungal infectionsOpsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodiesPeptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development.T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infectionMolecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cellProtection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts.Detection and quantitation of the glucuronoxylomannan-like polysaccharide antigen from clinical and nonclinical isolates of Trichosporon beigelii and implications for pathogenicity
P2860
Q24533456-48A432DB-9C3A-4BDE-A1E1-A44DBFAE3B37Q24683790-2E01B280-E893-44BB-9C91-A246F2418841Q26776056-1026A834-96BB-43E5-95AB-D70AB42FE306Q26823438-EE5AE32D-2C25-4456-B930-DB68E385249DQ28818603-1AFA947A-B08F-403B-9503-24FF4557EBDDQ30387948-A134660D-E725-4114-87E2-489AEBD37AC1Q30424017-3DEC9639-B0E8-4D1C-BF91-FB1B032DFEFEQ33334776-AA8EE641-9A52-4342-BD93-251404C5B51CQ33693515-511791F1-F857-483D-AD70-ABD186DC09FBQ33751509-429738D1-ACEC-4A82-9271-AAD078509C21Q33752366-446451C4-18D3-4460-8D20-DCF3EAD33A44Q33752377-ED60623A-BB2E-46CC-AE85-A29672BCD4CBQ34001701-9947D34F-6446-4062-AF7A-7CAB0AD811B8Q34001769-0CFC20BA-7FE2-41AD-8728-5A3422FD7432Q34003328-A5D3E6B1-7912-4DB1-B0CC-3576C8D3C1F7Q34006122-127B095B-0B34-48C6-92B4-FB80315E30FEQ34099803-91B8585B-7C5B-416C-832F-6C7E2344C5BBQ34400044-5E322095-CDE3-42A5-8A04-A84CBDB00B50Q34404601-B3BF9128-E3BB-42C9-B24C-6AFFCF072875Q34594241-8D36441B-D11F-4D97-AD1A-3E67700EEB42Q34779166-A2A29724-14F5-4FE9-AF7D-F71C5CC5E91AQ35085200-B2B80D4A-4712-42AC-B5F4-21B18218CA9EQ35115708-B7E471EE-948D-4517-B096-AC200848EA94Q35374928-089CF818-DE0A-40A1-9CFE-54A4DC6C042EQ35386000-9F0D780D-E3CA-47C4-8700-118B48971125Q35411136-C73D935C-782B-42F7-B7E3-641EB729E9E6Q35427366-364D51CE-9596-4168-846F-AE5E258FADC1Q35428887-903CC2FF-9C85-473F-9AFA-FF50C0CF29B8Q35447692-F7D2433D-CACC-49B8-9E74-DCAEAAC4D96CQ35514947-2EBD044A-F2B5-4E3E-8B28-1EC38A7C3CEEQ35544888-D234E751-5420-4843-9EE1-98C17BC6454DQ35567548-8DD65304-A0FD-47AD-8D02-6BAB987D538BQ35775466-4087294B-6AA4-4E04-A336-5A0EF39F7A36Q35938253-DF822677-58EA-4CE2-8C7F-0DECFACDD2D0Q36047782-61E0BD21-BD0A-43C5-81B7-68601A56B6FBQ36255421-3FFBD55C-D0B1-4141-A431-5B2BDB2384E4Q36361541-D941B8F6-6FAC-4358-8A9D-A66170DE193BQ36364342-B29EE1AD-6FBB-4A0D-B144-B1B90577B0BCQ36431583-8F27BA5A-598B-449B-8935-5B7BB9AAF503Q36517209-10E59C03-3A10-44FA-A96C-8E68835FF369
P2860
Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Cryptococcus neoformans seroty ...... erization, and immunogenicity.
@en
type
label
Cryptococcus neoformans seroty ...... erization, and immunogenicity.
@en
prefLabel
Cryptococcus neoformans seroty ...... erization, and immunogenicity.
@en
P2093
P2860
P1476
Cryptococcus neoformans seroty ...... erization, and immunogenicity.
@en
P2093
Bennett JE
Robbins JB
Schneerson R
P2860
P304
P407
P577
1991-10-01T00:00:00Z